Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy
The purpose of this study is to look at several genes that might determine how the body processes the drugs used to treat lung, colorectal and head and neck cancers. The goal of this examination is to help investigators determine the proper dosage to give future cancer patients or to better predict which future patients will respond to particular drug therapies.
Checked against the public recordLast updated Nov 28, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Kansas Medical Center
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Lung, Colorectal and Head and Neck Cancer Patients that have received or plan to receive chemotherapy as part of their treatment Exclusion Criteria: * Colorectal cancer patients that have never received or will not receive chemotherapy as part of their therapy * Head and Neck cancer patients that have never received or will not receive chemotherapy as part of their treatment * Patients with cancer types other than colorectal or head and neck * Unable to give informed consent
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Kansas Medical CenterKansas City, Kansas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 28, 2016. Always confirm current availability with the study team.